|Bid||11.05 x 0|
|Ask||12.95 x 0|
|Day's range||11.60 - 12.50|
|52-week range||10.98 - 53.60|
|Beta (5Y monthly)||1.18|
|PE ratio (TTM)||N/A|
|Earnings date||28 Jun 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||175.00|
OXFORD, England, June 21, 2022--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, has announced that its flagship Checkpoint inhibitor Response Test (CiRT) clinical blood test is now available to private physicians considering ICI therapy for their patients in the UK.
OXFORD, England, February 25, 2022--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on its EpiSwitch 3D genomics platform, has announced the successful clinical validation and US launch of its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT).
Just because a business does not make any money, does not mean that the stock will go down. For example, although...